Dr. Reddy’s (NYSE: RDY) approves new ESOP and ADR stock option grants
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories Limited has approved new employee stock option grants. The committee granted 8,16,119 Indian stock options under the 2018 ESOP and 3,76,115 ADR stock options under the 2007 ADR scheme, each with an exercise price of Rs. 1,293.90 per share.
Both grants are in line with SEBI Share Based Employee Benefits and Sweat Equity Regulations, 2021, and will vest 100% at the end of 3 years, providing long‑term equity incentives for eligible employees across Indian and ADR programs.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Employees Stock Option Scheme, 2018 financial
Employees ADR Stock Option Scheme, 2007 financial
American Depository Receipts (ADRs) financial
vesting schedule financial
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
| Description of Exhibits |
|
|
|
99.1 | Intimation dated May 11, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
|
| ||
Date: May 11, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
May 11, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Ltd. (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
This is to inform that the Nomination, Governance and Compensation Committee of the Board of Directors of the Company at its meeting held on May 11, 2026, has approved the grant of stock options to the eligible employees under the Employees Stock Option Schemes of the Company:
Sl. No. | Type of Option(s) | Number of options granted | Value | Exercise Price per share | ESOP Scheme |
1 | Indian Stock Options
| 8,16,119
| Fair Market Value | Rs. 1,293.90/- | Dr. Reddy’s Employees Stock Option Scheme, 2018 |
2 | American Depository Receipts (ADRs) Stock Options | 3,76,115 | Fair Market Value | Rs. 1,293.90 /- | Dr. Reddy's Employees ADR Stock Option Scheme, 2007
|
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K. Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
BRIEF DETAILS ON THE GRANT OF STOCK OPTIONS
(Pursuant to SEBI Master Circular No. HO/49/14/14(7)2025‐CFD‐POD2/I/3762/2026
dated January 30, 2026)
S.No | Particulars | Details | |
1. | Brief details of options granted | Grant of 8,16,119 under Dr. Reddy’s Employees Stock Option Scheme, 2018, to the eligible employees of the company. | Grant of 3,76,115 stock options under Dr. Reddy's Employees ADR Stock Option Scheme, 2007 to the eligible employees of the company. |
2. | Whether the scheme is in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (if applicable) | Yes | Yes |
3. | Total number of shares covered by these options | 8,16,119 | 3,76,115 |
4. |
| Rs. 1,293.90/- per stock option | Rs. 1,293.90/- per stock option |
5. | Options vested / vesting schedule | 100% vesting at the end of 3 years | 100% vesting at the end of 3 years |
6. | Time within which option may be exercised | According to respective vesting schedule | According to respective vesting schedule |
7. | Brief details of significant terms | Stock options granted are governed under the Dr. Reddy’s Employees Stock Option Scheme, 2018, which is administered and implemented by the Nomination, Governance & Compensation Committee | Stock options granted are governed under the Dr. Reddy's Employees ADR Stock Option Scheme, 2007, which is administered and implemented by the Nomination, Governance & Compensation Committee |
8. | Options exercised | Not Applicable | Not Applicable |
9. | Money realized by exercise of options |
|
|
10. | The total number of shares arising as a result of exercise of option |
|
|
11. | Options lapsed |
|
|
12. | Variation of terms of options |
|
|
13. | Subsequent changes or cancellation or exercise of such options |
|
|
14. | Diluted earnings per share pursuant to issue of equity shares on exercise of options |
|
|